Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143038 · ClinicalTrials.gov registry record · Phase 2
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01143038 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 75 participants.
The verdict
NCT01143038, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.
Interventions
- BIOLOGICAL Romiplostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-11-30 |
| Est. Completion | 2013-12-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143038
The ClinicalTrials.gov registry entry for NCT01143038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Romiplostim is the first listed.
NCT01143038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143038 about?
NCT01143038 is a clinical study titled "Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim". The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.
What is the current status of trial NCT01143038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2010-11-30. Estimated completion is 2013-12-26.
What interventions are being tested in trial NCT01143038?
The interventions under investigation include: Romiplostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT01143038?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.